ATE520708T1 - Immunogenetische hiv-1 multi-klade, multivalente konstrukte und deren verwendung - Google Patents
Immunogenetische hiv-1 multi-klade, multivalente konstrukte und deren verwendungInfo
- Publication number
- ATE520708T1 ATE520708T1 AT04749556T AT04749556T ATE520708T1 AT E520708 T1 ATE520708 T1 AT E520708T1 AT 04749556 T AT04749556 T AT 04749556T AT 04749556 T AT04749556 T AT 04749556T AT E520708 T1 ATE520708 T1 AT E520708T1
- Authority
- AT
- Austria
- Prior art keywords
- nucleic acid
- acid molecules
- hiv
- epitopes
- encode
- Prior art date
Links
- 241000713772 Human immunodeficiency virus 1 Species 0.000 title abstract 2
- 230000002998 immunogenetic effect Effects 0.000 title 1
- 102000039446 nucleic acids Human genes 0.000 abstract 5
- 108020004707 nucleic acids Proteins 0.000 abstract 5
- 150000007523 nucleic acids Chemical class 0.000 abstract 5
- 108090000623 proteins and genes Proteins 0.000 abstract 3
- 102000004169 proteins and genes Human genes 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 2
- 230000008685 targeting Effects 0.000 abstract 2
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 abstract 1
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 abstract 1
- 108700010908 HIV-1 proteins Proteins 0.000 abstract 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 210000000987 immune system Anatomy 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 230000037361 pathway Effects 0.000 abstract 1
- 125000006850 spacer group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
- A61K2039/645—Dendrimers; Multiple antigen peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/06—Fusion polypeptide containing a localisation/targetting motif containing a lysosomal/endosomal localisation signal
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
- C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US45888003P | 2003-03-28 | 2003-03-28 | |
| PCT/US2004/009767 WO2004085466A2 (en) | 2003-03-28 | 2004-03-26 | Immunogenic hiv-1 multi-clade, multivalent constructs and methods of their use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE520708T1 true ATE520708T1 (de) | 2011-09-15 |
Family
ID=33098288
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04749556T ATE520708T1 (de) | 2003-03-28 | 2004-03-26 | Immunogenetische hiv-1 multi-klade, multivalente konstrukte und deren verwendung |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US7425611B2 (de) |
| EP (1) | EP1608675B1 (de) |
| AT (1) | ATE520708T1 (de) |
| AU (1) | AU2004223855B8 (de) |
| CA (1) | CA2519025A1 (de) |
| WO (1) | WO2004085466A2 (de) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9090673B2 (en) | 2003-12-12 | 2015-07-28 | City Of Hope | Synthetic conjugate of CpG DNA and T-help/CTL peptide |
| US7951377B2 (en) | 2005-08-23 | 2011-05-31 | Los Alamos National Security, Llc | Mosaic clade M human immunodeficiency virus type 1 (HIV-1) envelope immunogens |
| EP1917040A4 (de) * | 2005-08-23 | 2012-12-12 | Univ California | Polyvalenter impfstoff |
| WO2009056535A2 (en) * | 2007-10-29 | 2009-05-07 | Genimmune N.V. | Methods and kits for inducing a ctl response using a prime boost regimen |
| WO2011082422A2 (en) * | 2010-01-04 | 2011-07-07 | The Johns Hopkins University | Human immunodeficiency virus (hiv-1) highly conserved and low variant sequences as targets for vaccine and diagnostic applications |
| JP6406647B2 (ja) * | 2013-07-02 | 2018-10-17 | 公益財団法人がん研究会 | 細胞性免疫誘導ワクチン |
| US10238741B2 (en) | 2014-10-10 | 2019-03-26 | The Trustees Of Columbia University In The City Of New York | Nucleic acid constructs for presentation of CD4 and CD8 epitopes, cellular transfection and uses thereof |
| WO2016057986A1 (en) * | 2014-10-10 | 2016-04-14 | The Trustees Of Columbia University In The City Of New York | Tandem epitope constructs for presentation of cd4 and cd8 epitopes and uses thereof |
| EP3927372A4 (de) * | 2019-02-21 | 2023-01-25 | Centivax, Inc. | Optimierte impfstoffzusammensetzungen und verfahren zu deren herstellung |
| WO2020186064A1 (en) * | 2019-03-12 | 2020-09-17 | The General Hospital Corporation | Highly networked immunogen composition |
| WO2021011544A1 (en) | 2019-07-16 | 2021-01-21 | Gilead Sciences, Inc. | Hiv vaccines and methods of making and using |
| WO2021185851A1 (en) * | 2020-03-17 | 2021-09-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Vaccine compositions for hiv prevention and treatment |
| CA3202466A1 (en) | 2021-01-14 | 2022-07-21 | Jiani LI | Hiv vaccines and methods of using |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5633234A (en) | 1993-01-22 | 1997-05-27 | The Johns Hopkins University | Lysosomal targeting of immunogens |
| US6319503B1 (en) | 1998-02-19 | 2001-11-20 | Proteinix Company | Heat shock fusion-based vaccine system |
| AU4078599A (en) | 1998-05-13 | 1999-11-29 | Epimmune, Inc. | Expression vectors for stimulating an immune response and methods of using the same |
| US20020182222A1 (en) | 1998-07-10 | 2002-12-05 | Groot Anne De | HIV vaccine candidate peptides |
| WO2000029008A2 (en) | 1998-11-16 | 2000-05-25 | Board Of Regents, The University Of Texas System | Hiv-specific t-cell induction |
| AU6636800A (en) | 1999-08-13 | 2001-03-13 | Proteinix Company | Heat shock fusion-based vaccine system |
| ES2330078T3 (es) | 1999-09-16 | 2009-12-04 | Eisai Corporation Of North America | Acidos nucleicos que codifican polipeptidos poliepitope. |
| AU1075001A (en) | 1999-10-05 | 2001-05-10 | Epimmune, Inc. | Inducing cellular immune responses to human immunodeficiency virus-1 using peptide and nucleic acid compositions |
| MXPA02006379A (es) * | 1999-12-23 | 2004-06-21 | Medical Res Council | Mejoriasen o relacionadas con la respuesta inmune a vih. |
| US7462354B2 (en) | 1999-12-28 | 2008-12-09 | Pharmexa Inc. | Method and system for optimizing minigenes and peptides encoded thereby |
| EP1130089A1 (de) * | 2000-02-17 | 2001-09-05 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Membranvirus Ziel- und Fusion-subvirale Partikel enthaltende Zusammensetzung und diese enthaltende Impstoff |
| DE10010292A1 (de) | 2000-03-02 | 2001-09-06 | Zahnradfabrik Friedrichshafen | Fahrzeugachse |
| ES2386884T3 (es) | 2000-11-01 | 2012-09-04 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Vectores de expresión capaces de inducir respuesta inmunomejorada y métodos para usarlos |
| US20030003440A1 (en) * | 2001-03-14 | 2003-01-02 | Lucia Lopalco | Novel CCR5 epitope and antibodies against it |
| AU2002307145B2 (en) | 2001-04-05 | 2007-11-29 | The John Hopkins University | Chimeric vaccines |
| CA2357906A1 (en) | 2001-09-28 | 2003-03-28 | Institut Pasteur | Identification of new cd8 epitopes from hiv-1 proteins with therapeutical and vaccinal properties against hiv infections |
| KR100996330B1 (ko) | 2002-05-16 | 2010-11-23 | 버베리안 노딕 에이/에스 | Ｈｉｖ 조절/부속 단백질의 융합 단백질 |
-
2004
- 2004-03-26 CA CA002519025A patent/CA2519025A1/en not_active Abandoned
- 2004-03-26 US US10/550,651 patent/US7425611B2/en not_active Expired - Fee Related
- 2004-03-26 AT AT04749556T patent/ATE520708T1/de not_active IP Right Cessation
- 2004-03-26 AU AU2004223855A patent/AU2004223855B8/en not_active Ceased
- 2004-03-26 WO PCT/US2004/009767 patent/WO2004085466A2/en not_active Ceased
- 2004-03-26 EP EP04749556A patent/EP1608675B1/de not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| AU2004223855A1 (en) | 2004-10-07 |
| WO2004085466A3 (en) | 2005-03-24 |
| EP1608675B1 (de) | 2011-08-17 |
| US7425611B2 (en) | 2008-09-16 |
| US20060216305A1 (en) | 2006-09-28 |
| AU2004223855B8 (en) | 2011-03-17 |
| CA2519025A1 (en) | 2004-10-07 |
| WO2004085466A8 (en) | 2005-10-13 |
| EP1608675A2 (de) | 2005-12-28 |
| AU2004223855B2 (en) | 2010-06-17 |
| WO2004085466A2 (en) | 2004-10-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR129651A2 (es) | Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos | |
| PH12020551907A1 (en) | Antagonizing cd73 antibody | |
| CY1122576T1 (el) | Ανθρωπινα αντισωματα που δεσμευουν το γονιδιο-3 ενεργοποιησης λεμφοκυτταρων (leg-3), και χρησεις εξ' αυτων | |
| NO20064059L (no) | Albumin fusjonsproteiner | |
| EA202091710A1 (ru) | Антитела против cd73 и способы их применения | |
| ATE520708T1 (de) | Immunogenetische hiv-1 multi-klade, multivalente konstrukte und deren verwendung | |
| ATE533782T1 (de) | Impfstoffe und immuntherapeutika mit codon- optimiertem il-15 und verwendungsverfahren dafür | |
| BR112018072946A2 (pt) | proteínas de fusão a gdf15 e usos das mesmas | |
| MX2019006045A (es) | Proteinas triespecificas dirigidas a psma y metodos de uso. | |
| BRPI1008692B8 (pt) | anticorpo antagonista tendo especificidade para ox40 humano, sequência de dna isolado, vetor de clonagem ou de expressão, célula hospedeira, processo para a produção do referido anticorpo, composição farmacêutica, uso do 5 referido anticorpo e proteína de fusão | |
| MX2009002816A (es) | Proteinas de fusion de albumina. | |
| MX2008001865A (es) | Proteinas de fusion de albumina. | |
| MX383614B (es) | Proteinas de union triespecificas y metodos de uso. | |
| BRPI0507489A (pt) | anticorpos humanos de anti-cd38 e para os seus usos | |
| EA200702093A1 (ru) | Антитела-миметики glp-1 человека, композиции, способы и их применение | |
| NO20091387L (no) | Antistoffer mot benmorfogene proteiner og reseptorer derav, fremgangsmater for deres anvendelse | |
| EA201491171A1 (ru) | Вещества, содержащие улучшенные генетические конструкции il-12, вакцины, иммунотерапевтические составы и способы их применения | |
| UY31533A1 (es) | Moleculas de enlace al receptor humano ox40 | |
| AR072680A1 (es) | Axmi-115 axmi-113 axmi-005 axmi-163 y axmi-184 proteinas insecticidas y metodos de uso de las mismas | |
| EA202190267A1 (ru) | Способы и композиции с использованием рекомбинантных дендритных клеток для терапии рака | |
| DK2054431T3 (da) | Konformere af bakterielle adhæsiner | |
| Leblanc et al. | VaxCelerate II: rapid development of a self-assembling vaccine for Lassa fever | |
| ATE473236T1 (de) | Antigene von piscirickettsia salmonis und deren verwendung | |
| EA202191658A1 (ru) | Антитела против фактора c2b комплемента человека и способы применения | |
| Martelet et al. | Porcine dendritic cells as an in vitro model to assess the immunological behaviour of Streptococcus suis subunit vaccine formulations and the polarizing effect of adjuvants |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |